On May 13, 2021 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported that Nai-Kong V. Cheung, MD, PhD, Enid A. Haupt Endowed Chair, Pediatric Oncology, Memorial Sloan Kettering Cancer Center ("MSK") will present a research update on the Company’s SADA technology platform at PEGS Boston Virtual Conference on May 13, 2021 at 1:20 p.m. Eastern Time (Press release, Y-mAbs Therapeutics, MAY 13, 2021, View Source [SID1234579902]). The SADA technology was licensed by the Company from MSK and the Massachusetts Institute of Technology ("MIT").
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Cheung’s presentation will focus on cancer therapeutics failing in development because of dose-limiting toxicities or subtherapeutic dosing as a consequence of insufficient therapeutic index ("TI"). The two step SADA technology uses unique pharmacokinetics to potentially improve the TI. When applied to pre-targeted radioimmunotherapy ("PRIT"), the bispecific SADA antibodies visualize tumors with high precision using PET (diagnostic approach) and has been shown to ablate aggressive solid tumors using both beta and alpha emitters such as 177Lu or 225Ac (therapeutic approach), potentially without significant toxicity to bone marrow, liver, kidney, or CNS. Furthermore, the modularity of the SADA platform might allow easy adaptation to different tumor targets and a variety of payloads.
Researchers at MSK, including Dr. Cheung, developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs. Dr. Cheung has intellectual property rights and interests in the technology, and as a result of this licensing arrangement, MSK has institutional financial interests in the technology and Y-mAbs.